YMRC
SRPT icon

Yorktown Management & Research Company’s Sarepta Therapeutics SRPT Stock Holding History

Yorktown Management & Research Company’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,600
Closed -$559K – 233
2024
Q4 		$559K Buy
+4,600
New +$564K 0.54% 62

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Yorktown Management & Research Company's SRPT Position: Q1 2025 in Review

Yorktown Management & Research Company sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 4,600 shares — an estimated $559K sold.

Yorktown Management & Research Company first reported a position in SRPT in Q4 2024 and held it in 1 quarter. The position peaked at $559K in Q4 2024. 431 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Yorktown Management & Research Company reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Yorktown Management & Research Company sold 4,600 Sarepta Therapeutics shares in Q1 2025, an estimated $559K.
  • Yorktown Management & Research Company first reported a position in Sarepta Therapeutics in Q4 2024 and held it in 1 quarter.
  • Yorktown Management & Research Company's Sarepta Therapeutics position peaked at $559K in Q4 2024.
  • 431 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Yorktown Management & Research Company's 13F filing for Q1 2025, filed 23 Apr 2025.